MARKET

NERV

NERV

Minerva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.96
+0.26
+4.56%
Opening 14:44 11/22 EST
OPEN
5.73
PREV CLOSE
5.70
HIGH
6.10
LOW
5.70
VOLUME
323.24K
TURNOVER
--
52 WEEK HIGH
9.12
52 WEEK LOW
4.010
MARKET CAP
232.59M
P/E (TTM)
-4.1880
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NERV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NERV News

  • Edited Transcript of NERV earnings conference call or presentation 4-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.1d ago
  • Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019
  • GlobeNewswire.11/14 13:30
  • Minerva Neurosciences, Inc (NERV): Are Hedge Funds Right About This Stock?
  • Insider Monkey.11/11 05:10
  • Minerva Neurosciences Inc (NERV) Q3 2019 Earnings Call Transcript
  • MotleyFool.com.11/04 18:00

More

Industry

Biotechnology & Medical Research
+1.69%
Pharmaceuticals & Medical Research
+0.75%

Hot Stocks

Name
Price
%Change

About NERV

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.
More

Webull offers Minerva Neurosciences Inc (NERV) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.